Sanofi steps up with a $645M deal to part­ner with As­traZeneca on a late-stage RSV an­ti­body

Point­ing di­rect­ly at a piv­otal Phase III pro­gram, As­traZeneca has de­cid­ed to part­ner with Sanofi on an ex­per­i­men­tal an­ti­body for RSV.

The French phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA